Article
Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.
BMC Pulm Med. 2017 Dec 28; 17 (1): 216.
Multicenter Study
Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Respir Med. 2017 Jan 1; 122 Suppl 1: S18-S22.